Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.15)
# 1,072
Out of 4,829 analysts
485
Total ratings
39.63%
Success rate
1.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTVA MetaVia | Reiterates: Buy | $12 | $0.73 | +1,546.09% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $7.5 | $0.55 | +1,263.64% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $10.98 | +446.45% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $2.55 | +194.12% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $3.62 | +259.12% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $1.38 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.54 | +1,011.32% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $4.48 | +1,462.50% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.73 | - | 13 | Mar 27, 2025 | |
| ASMB Assembly Biosciences | Reiterates: Neutral | n/a | $12.24 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.36 | +3,233.33% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.41 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $3.26 | +881.60% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $18.63 | +87.87% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $39.85 | +88.21% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $7.71 | +172.55% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $44.27 | +62.64% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $299.69 | +35.14% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $3.62 | +51.93% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $35.11 | +170.58% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.27 | +241.56% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.30 | +202.33% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.23 | +54.80% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $22 | $20.02 | +9.89% | 20 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $18.37 | +161.30% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $3.04 | +146.71% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.02 | +390.20% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $8.00 | +62.50% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $0.53 | +45,423.52% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.12 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $21.71 | +15.15% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.24 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $23.96 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $27.55 | -74.59% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $28.89 | -27.31% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.72 | - | 2 | Feb 15, 2017 |
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.73
Upside: +1,546.09%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $7.5
Current: $0.55
Upside: +1,263.64%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $10.98
Upside: +446.45%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $2.55
Upside: +194.12%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $3.62
Upside: +259.12%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.54
Upside: +1,011.32%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $4.48
Upside: +1,462.50%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.73
Upside: -
Assembly Biosciences
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $12.24
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $12
Current: $0.36
Upside: +3,233.33%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.41
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $3.26
Upside: +881.60%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $18.63
Upside: +87.87%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $39.85
Upside: +88.21%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $7.71
Upside: +172.55%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $44.27
Upside: +62.64%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $299.69
Upside: +35.14%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $3.62
Upside: +51.93%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $35.11
Upside: +170.58%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $5.27
Upside: +241.56%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $4.30
Upside: +202.33%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.23
Upside: +54.80%
Jan 15, 2025
Maintains: Buy
Price Target: $18 → $22
Current: $20.02
Upside: +9.89%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $18.37
Upside: +161.30%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $3.04
Upside: +146.71%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.02
Upside: +390.20%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $8.00
Upside: +62.50%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $0.53
Upside: +45,423.52%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $21.71
Upside: +15.15%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.24
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $23.96
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $27.55
Upside: -74.59%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $28.89
Upside: -27.31%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $2.72
Upside: -